期刊文献+

血清中肿瘤标志物联合检测在乳腺癌早期诊断中的研究 被引量:1

原文传递
导出
摘要 乳腺癌好发于40~60岁妇女,发病隐匿,早期一般无明显不适,往往容易被忽略,错失最佳治疗时机,确诊时已为晚期1-3,为患者带来了很大痛苦。血清CA153、CA125和CA199均为肿瘤标志物,我们通过化学发光法对血清CA153、CA125和CA199进行测定,以便研究血清CA153、CA125和CA199的变化,达到尽早诊断乳腺癌的目的,现将结果报告如下。
作者 方菲 谢淑华
出处 《中国肿瘤临床与康复》 2014年第5期540-541,共2页 Chinese Journal of Clinical Oncology and Rehabilitation
关键词 联合检测 肿瘤标志物 乳腺肿瘤 临床价值 Joint detection Tumor markers Breast neoplasms Clinical value
  • 相关文献

参考文献6

二级参考文献45

  • 1唐劲光.血清肿瘤标志在恶性肿瘤的表现与临床意义[J].广西医学院学报,2000,17(6):1049-1050. 被引量:3
  • 2汪意青,方庆安,陈玉泉,陈瑞新,于秀.乳腺癌患者血清CA15-3的临床意义[J].南通医学院学报,1996,16(3):333-334. 被引量:3
  • 3张允平,蔡振范.Graves病患者血清可溶性白介素2受体水平及临床意义[J].标记免疫分析与临床,1996,3(3):172-173. 被引量:35
  • 4张清媛,李贺书,王树滨,刘旭,赵毓芝.CA15-3在乳腺癌诊断和监测中的应用[J].中国肿瘤临床,1997,24(1):57-58. 被引量:8
  • 5赵庆荣.糖链抗原CA19-9 RIA诊断消化道癌临床意义[J].中华核医学杂志,1987,7(2):75-75.
  • 6宁连胜 国爱英 黄建英.乳腺癌单克隆抗体CA15-3的临床应用[J].中国肿瘤临床,1987,14(6):327-328.
  • 7[1]Fuhrman C, Duche JC, Chouaid C, et al. Use of tumor markers for differential diagnosis of mesothelioma and secondary pleural malignancies. Clin Biochem,2000,33(5):405-410.
  • 8[2]Alatas F, Alatas O, Metintas M, et al. Diagnostic value of CEA, CA 15-3, CA 19-9, CYFRA 21-1, NSE and TSA assay in pleural effusions. Lung Cancer,2001,31(1):9-16.
  • 9[3]Miedouge M, Rouzaud P, Salama G, et al. Evaluation of seven tumor markers in pleural fluid for the diagnosis of malignant effusions. Br J Cancer,1999,81(6):1059-1065.
  • 10[4]Ando S, Kimura H, Iwai N, et al. Optimal combination of seven tumor markers in prediction of advanced stage at first examination of patients with non-small cell lung cancer. Anticancer Res,2001,21(4B):3085-3092.

共引文献181

同被引文献15

  • 1潘祥林,王鸿利.诊断学的任务与发展方向[J].中华诊断学电子杂志,2013,1(1). 被引量:51
  • 2王刚平,张红,梁云爱,张作峰,袁宗怀,郭小艳.β-tubulin-Ⅲ、E-cadherin和α-catenin在乳腺癌及癌前病变中的表达及诊断意义[J].中华诊断学电子杂志,2013,1(1). 被引量:8
  • 3Evans EE, Henn AD, Jonason A,et al.C35 (C 17orf37 ) is a novel tumor biomarker abundantly expressed in breast cancer [ J ]. Mol Cancer Ther,2006,5(11) :2919-2930.
  • 4Rakha EA, E1-Sayed ME, Powe DG, et al.Invasive lobular carcinoma of the breast:Response to hormonal therapy and outcomes [ J ].Eur J Cancer,2008,44( 1 ) :73-83.
  • 5Arpino G,Bardou VJ,Clark GM, et al.Infihrating lobular carcinoma of the breast : tumor characteristics and clinical outcome [ J ]. Breast Cancer Res,2004,6(3) : 149-156.
  • 6Duffy MJ.Serum tumor markers in breast cancer:are they of clinical value [ J ].Clin Chem,2006,52 (3) : 345-351.
  • 7Gion M,Mione R,Leon AE,et al. CA27.29:a valuable marker for breast cancer management[ J].Eur J Cancer,2001,37(3) :355-363.
  • 8Bartlett J, Mallon E, Cooke T. The clinical evaluation of HER-2 status:which test to use? [J] .J Pathol,2003,199(4) :411-417.
  • 9Maurer-Stroh S, Eisenhaber F.Refinement and prediction of protein prenylation motifs [ J ]. Genome Biol, 2005,6 (6) : R55.
  • 10Yang CJ, Chang CF, Huang LY, et al. Resonance assignments of human C35 (C17off37) protein, a novel tumor biomarker [ J ]. Biomol NMR Assign,2010,4(2) :191-193.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部